A
Amplifybio
Advances translational science, cell and gene therapies and next-generation medicines for the benefit of millions of people around the world
About Amplifybio
AmplifyBio is a preclinical Contract Research Organization (CRO) and R&D outsourcing partner that specializes in the development and manufacturing of next-generation therapies. These therapies include cell, gene, mRNA, and other advanced modalities. The company operates in the biotechnology and pharmaceutical market, serving clients who are in the process of developing new therapeutic treatments.
AmplifyBio's business model is based on offering outsourced R&D solutions for benchmarking next-generation therapeutics. This includes discovery, optimization, and characterization services. Additionally, they offer safety, efficacy, and toxicology services, providing a comprehensive preclinical CRO solution built on a foundation of expertise and experience.
The company has recently expanded its services to include a Manufacturing Enablement Center. This new business unit offers manufacturing partnerships for multiple modalities, with flexible contract staffing models to meet varied client requirements.
AmplifyBio generates revenue through these contract services, charging clients for the research, development, and manufacturing services they provide. The company has received positive feedback from clients for its collaborative approach, expertise, and efficiency.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- West Jefferson, United States
- Employees
- 62
- Open positions
- None listed
- Dealroom signal
- 26.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jan 2026
- Capital deployed
- $20M
- Preferred round
- SEED
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Nov 2024 | $50M | $200M | Vitrian | ↗ |
| GROWTH EQUITY VCOther financing | Nov 2023 | $50M | — | Narya Capital · Casdin Capital · Viking Capital | ↗ |
Growth signals
Latest recorded traffic for Amplifybio is 390 monthly website visits, down 79.5% over the last three months. Amplifybio's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
Hercules Capital
Narya Capital
Casdin Capital
Viking Capital
Vitrian
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Amplifybio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Amplifybio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.